ArticleScientific reports2023

Pharmacological inhibition of BCL-2 with the FDA-approved drug venetoclax impairs longitudinal bone growth.

Lilly Velentza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.